Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate-2/high International Prognostic Score System risk, safety and efficacy data in intermediate-1 patients are limited. We report on 70 intermediate-1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG-MRT criteria. At 6 months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3 months, ruxolitinib-induced grade 3 anemia and thrombocytopenia occurred in
40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most (82.6%) patients were still on therapy after a median follow-up of 27 months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects. Myelofibrosis (MF) is a progressive disease that is burdened by symptomatic splenomegaly, debilitating systemic symptoms, worsening cytopenias, and overall reduced survival. 1 Prognosis is currently assessed by the International Prognostic Scoring System (IPSS) at diagnosis, 2 by the dynamic-IPSS (DIPSS) over the follow-up, 3 and by the DIPSS-plus that includes also transfusion requirement, thrombocytopenia, and cytogenetic abnormalities. 4 Molecular abnormalities including driver (JAK2 V617F /CALR/MPL) and subclonal (ASXL1/SRSF2) mutations have been recently integrated in the mutation-enhanced IPSS (MIPSS) score. 5 Balancing life expectancy (ranging between 6.5 and 14. Ruxolitinib is the first-in-class JAK1/JAK2 inhibitor currently available for the treatment of MF-related splenomegaly and/or symptoms. 6, 7 The registrative COMFORT studies randomized intermediate- 
| Spleen and symptom responses
Per intention-to-treat analysis, 42 (60%) patients achieved a spleen response or symptom reduction by 24 months (Figure 1 
| Treatment discontinuation and overall survival
A total of 12 (17.1%) patients discontinued RUX after a median time of 9.3 months (1-28.8). Reasons for treatment discontinuation were acute renal failure (1 case), lung cancer (1), disease progression without evolution into acute leukemia (2), infectious complication (bone TBC, 1 case), evolution into acute leukemia (1), and lack or loss of response (6) .
Both patients that experienced a disease progression during ruxolitinib therapy with enlarging splenomegaly and worsening symptoms were submitted to alloSCT soon after ruxolitinib discontinuation. Overall, 4
patients died because of lung cancer, acute renal failure, complication after allogeneic transplant, and disease progression without acute evolution. Death occurred after a mean RUX exposure of 6.6 months (standard deviation, 4.4); in no case the death was directly attributed to therapy. Survival at 2 years was 80.1% for a median survival of 56.7 months.
| DISCUSSION
In real-world clinical practice, a substantial proportion of patients with intermediate-1 risk MF may require ruxolitinib therapy. In the present report, at 6 months, we observed a rate of spleen responses (54.7%)
that was comparable to that observed at week 24 in the 14 intermediate-1 risk patients enrolled in the UK ROBUST trial (57.1%). (65.2%) patients received ruxolitinib because of severe/symptomatic splenomegaly front-line or after failure of conventional therapy. In the remaining cases, ruxolitinib was administered to less symptomatic patients. The probability to achieve a spleen response at 6 months was not influenced by baseline disease severity (51.2% in patients treated according to ELN-SIE recommendations versus 60.9% in patients treated with less advanced disease, P = .60). The rate of symptom responses at 6 months was also comparable (78% versus 87%, P = .51). Additionally, the incidence of drug-induced anemia at 3 months was comparable among the 2 cohorts (37.8% versus 25%, P = .24). There is an ongoing debate on the use of ruxolitinib in intermedi- 
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